Related Experiment Videos
[Pseudotumor cerebri in children]
M Piotropawłowska-Weinert1, B Szafrańska
1I. Kliniki Pediatrycznej Pomorskiej Ak. Med., Szczecinie.
Insights
Brain pseudotumours in children mimic brain tumors, presenting with headaches and vision changes. Treatment with fluid restriction and medication successfully resolved symptoms in all observed cases.
Area of Science:
- Pediatric Neurology
- Ophthalmology
- Radiology
Background:
- Brain pseudotumors are a diagnostic challenge in pediatric neurology.
- Symptoms like headaches and visual disturbances can mimic serious neurological conditions.
- Accurate diagnosis is crucial for appropriate management and to avoid unnecessary interventions.
Observation:
- Six pediatric cases (ages 3-15) were observed with suspected brain tumors.
- Patients presented with headaches, funduscopic changes, nystagmus, squint, vomiting, and dizziness.
- Some cases also had concurrent pharyngitis or sinusitis.
Findings:
- Contrast-enhanced brain imaging was normal in all patients.
- Treatment involved salt/fluid restriction and edema-reducing drugs (glycerol, mannitol, decadron).
- Neurological and ophthalmological signs showed significant regression within 3 to 12 weeks.
Implications:
- This study highlights the importance of considering brain pseudotumors in pediatric differential diagnoses.
- Conservative management strategies can be effective for pediatric brain pseudotumors.
- Early recognition and treatment can lead to favorable outcomes, preventing invasive procedures.
Abstract:
The authors observed 6 cases of brain pseudotumours in children aged from 3 to 15 years. All patients had been referred with the diagnosis of brain tumour, with headaches, eye fundus changes fundus changes. Some children had nystagmus, squint, vomiting and dizziness. One child had pharyngitis, two had sinusitis. Contrast brain examinations gave normal results. Diet with salt and fluid restriction and oedema-reducing drugs (glycerol, mannitol, decadron) were used. In all patients the neurological and ophthalmological signs regressed within 3 to 12 weeks.